whitepaper
ebook: Guidance on implementation of ARMMs
Many quality control professionals recognise that the need to modernise microbial detection methods is at an all-time high.
List view / Grid view
Biosimilars
whitepaper
Resources: Single use technologies – the ultimate future
Single use technologies is highly booming in biopharmaceutical sector due to its efficient use and benefits.
whitepaper
Article: Outsourcing biologics: key considerations
PCI’s Tim Roberts discusses key factors when outsourcing the clinical and commercial supply of biologics, and what makes a strong CDMO partnership.
whitepaper
Case study: Reduce plate counts with rapid microbial monitoring
Find out how a pharma company maintained product quality and reduced plate counts by 25 percent using a rapid microbial monitoring analyser – the 7000RMS.
news
Altruistic initiatives aim to improve patient care in developing regions
Ambitions to reach greater numbers of patients with unmet need have fuelled some benevolent plans from bio/pharmaceutical companies ViiV Healthcare and Sandoz.
whitepaper
ebook: Proactive clinical supply planning
The importance of thoroughly planned resupply strategies in maintaining clinical supply inventories as studies move into late phase.
whitepaper
Article: Clinical and commercial outsourcing
The demand for biologics and high potent medicines is forcing the industry to consider alternatives, such as outsourcing and integrated solutions.
news
EMA’s human medicines committee (CHMP) May 2022 meeting highlights
The latest meeting saw EMA’s human medicines committee (CHMP) recommend the approval of nine new medicines, refuse two biosimilar medications and recommend extensions of therapeutic indication for six medicines.
whitepaper
Whitepaper: Data integrity and 21CFR.11 for 7000RMS implementation
Learn about 21CFR.11 and Annex 11 requirements and how you can implement a rapid bioburden analyser designed to meet compliant operation needs.
video
On-demand webinar: Mould contamination, investigation and remediation challenges
Most industries face mould contamination issues, including medical products, hospitals, cosmetics, paint, among others. Learn more about mould and what you can do to combat it.
![Samsung Biologics logo on a phone screen [Credit: viewimage/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Samsung-biologics-300x278.jpg)
![Samsung Biologics logo on a phone screen [Credit: viewimage/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Samsung-biologics-e1650536525880.jpg)
news
Samsung Bioepis fully acquired by Samsung Biologics
After first payment of $1bn to Biogen, Samsung Biologics has now fully acquired Samsung Bioepis.
video
Video: Ami Polymer are specialists of tubings, hose and SUS assemblies
Ami Polymer are experts in manufacture of silicone tubing, hose and single use assembly with PPE components, which is demanded in pharma/biopharma industry.
news
EMA’s human medicines committee (CHMP) Feb meeting highlights
Highlights of the February 2022 meeting of EMA’s human medicines committee (CHMP) include the recommendation of 13 medicines for approval, along with updates to other drugs and COVID-19 vaccines.
news
CHMP meeting highlights, January 2022
The EMA’s Human Medicines Committee (CHMP) recommended approval of Paxlovid for COVID-19 and a new gene therapy for large B-cell lymphomas.
whitepaper
Article: Evolving into an international biotech market driver
In 20 years BIOCAD grew from a pharma startup outside of Moscow to an international company producing both biosimilars and original products.
